Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Acta Marisiensis - Seria Medica
Volume 68 (2022): Issue 1 (March 2022)
Open Access
Risk Assessment of Failures in Generic Drug Development and Approval Procedure under Competitive Generic Drug Therapy and Patent Challenge Exclusivities Provided by the United States Food and Drug Administration
M Vivek Reddy
M Vivek Reddy
,
GNK Ganesh
GNK Ganesh
,
B Babu
B Babu
,
Ramesh Jagadeesan
Ramesh Jagadeesan
and
Praharsh Kumar MR
Praharsh Kumar MR
| Apr 13, 2022
Acta Marisiensis - Seria Medica
Volume 68 (2022): Issue 1 (March 2022)
About this article
Previous Article
Next Article
Abstract
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Published Online:
Apr 13, 2022
Page range:
28 - 34
Received:
Dec 06, 2021
Accepted:
Mar 07, 2022
DOI:
https://doi.org/10.2478/amma-2022-0004
Keywords
generic drug exclusivity
,
competitive generic therapy
,
patent challenge exclusivity
© 2022 M Vivek Reddy et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.